Literature DB >> 26778726

Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes.

Shen Hui Chuang1, Hung Chew Wong2, Anantharaman Vathsala3, Evan Lee3, Priscilla Pei Ching How3,4.   

Abstract

INTRODUCTION: A complex relationship exists between chronic kidney disease-mineral and bone disorder (CKD-MBD) and adverse outcomes among dialysis patients. This study aimed to report the prevalence of CKD-MBD and examine the impact of achieving target CKD-MBD parameters on morbidity and mortality one year after peritoneal dialysis (PD) initiation.
METHODS: In this retrospective cohort study, patients electively initiated on PD were followed up for one year. Laboratory parameters were collected and the prevalence of CKD-MBD 4-6 months after PD initiation was determined based on the Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Linear regression and Cox proportional hazards model were used to evaluate the effects of achieving CKD-MBD targets 4-6 months after PD initiation on hospitalisation, the incidence of peritonitis or exit-site infections (ESIs), and mortality at one year.
RESULTS: The prevalence of CKD-MBD among the 86 patients in this study was 86.0% (KDOQI) and 54.7% (KDIGO). There was no significant difference in hospitalisation duration between patients who achieved targets and those who did not. Patients who failed to meet all the KDIGO CKD-MBD or calcium serum targets had a higher incidence of peritonitis or ESI. A trend toward shorter time to death was observed among patients who failed to meet the KDIGO phosphorus serum targets.
CONCLUSION: There was moderate (KDIGO) to high prevalence (KDOQI) of CKD-MBD among the patients. Achievement of all the KDIGO CKD-MBD or calcium serum targets was associated with reduced peritonitis or ESI, while achievement of the KDIGO phosphorus serum targets was associated with improved survival. Copyright: © Singapore Medical Association

Entities:  

Keywords:  incident; mineral and bone disorder; outcomes; peritoneal dialysis; short-term

Mesh:

Year:  2015        PMID: 26778726      PMCID: PMC5331134          DOI: 10.11622/smedj.2015195

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  25 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

Review 2.  Metabolic bone disease in chronic kidney disease.

Authors:  Kevin J Martin; Esther A González
Journal:  J Am Soc Nephrol       Date:  2007-01-24       Impact factor: 10.121

3.  Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis.

Authors:  Wai-Kei Lo; Joanne M Bargman; John Burkart; Raymond T Krediet; Carol Pollock; Hideki Kawanishi; Peter G Blake
Journal:  Perit Dial Int       Date:  2006 Sep-Oct       Impact factor: 1.756

4.  Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis.

Authors:  K Scott Brimble; Michelle Walker; Peter J Margetts; Kiran K Kundhal; Christian G Rabbat
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

5.  Peritoneal calcification in a peritoneal dialysis patient: a case report.

Authors:  D M Francis; I Busmanis; G Becker
Journal:  Perit Dial Int       Date:  1990       Impact factor: 1.756

6.  Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.

Authors:  Navdeep Tangri; Martin Wagner; John L Griffith; Dana C Miskulin; Alexandra Hodsman; David Ansell; David M J Naimark
Journal:  Am J Kidney Dis       Date:  2010-12-04       Impact factor: 8.860

7.  Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.

Authors:  Eric W Young; Justin M Albert; Sudtida Satayathum; David A Goodkin; Ronald L Pisoni; Takashi Akiba; Tadao Akizawa; Kiyoshi Kurokawa; Jürgen Bommer; Luis Piera; Friedrich K Port
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

Review 8.  Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD).

Authors:  Wajeh Y Qunibi
Journal:  Kidney Int Suppl       Date:  2004-09       Impact factor: 10.545

Review 9.  [Roles of hyperphosphatemia in vascular calcification].

Authors:  Atsushi Shioi; Yoshiki Nishizawa
Journal:  Clin Calcium       Date:  2009-02

10.  Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Francesca Tentori; Margaret J Blayney; Justin M Albert; Brenda W Gillespie; Peter G Kerr; Jürgen Bommer; Eric W Young; Tadao Akizawa; Takashi Akiba; Ronald L Pisoni; Bruce M Robinson; Friedrich K Port
Journal:  Am J Kidney Dis       Date:  2008-06-02       Impact factor: 8.860

View more
  5 in total

1.  The impact of axial spondyloarthritis on quality of life (QoL): a comparison with the impact of moderate to end-stage chronic kidney disease on QoL.

Authors:  Yu Heng Kwan; Warren Fong; Priscilla How; Hwee-Lin Wee; Ying Ying Leung; Jie Kie Phang; Nai Lee Lui; Chuen Seng Tan; Rahul Malhotra; Truls Østbye; Julian Thumboo
Journal:  Qual Life Res       Date:  2018-06-05       Impact factor: 4.147

2.  Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations.

Authors:  Kamolpat Chaiyakittisopon; Oraluck Pattanaprateep; Narisa Ruenroengbun; Tunlanut Sapankaew; Atiporn Ingsathit; Gareth J Mckay; John Attia; Ammarin Thakkinstian
Journal:  Eur J Health Econ       Date:  2021-03-06

Review 3.  Past, Present, and Future of Phosphate Management.

Authors:  Simit M Doshi; Jay B Wish
Journal:  Kidney Int Rep       Date:  2022-02-01

4.  Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.

Authors:  Yemi R Raji; Samuel O Ajayi; Abiodun M Adeoye; Olukemi Amodu; Bamidele O Tayo; Babatunde L Salako
Journal:  Afr Health Sci       Date:  2022-03       Impact factor: 1.108

5.  Serum Alkaline Phosphatase Levels Predict Infection-Related Mortality and Hospitalization in Peritoneal Dialysis Patients.

Authors:  Seun Deuk Hwang; Su-Hyun Kim; Young Ok Kim; Dong Chan Jin; Ho Chul Song; Euy Jin Choi; Yong-Lim Kim; Yon-Su Kim; Shin-Wook Kang; Nam-Ho Kim; Chul Woo Yang; Yong Kyun Kim
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.